SNZZ.F Stock Overview
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Senzime AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.55 |
| 52 Week High | SEK 0.96 |
| 52 Week Low | SEK 0.55 |
| Beta | 0.59 |
| 11 Month Change | -10.13% |
| 3 Month Change | -22.86% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -66.67% |
| Change since IPO | -30.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNZZ.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 2.0% |
| 1Y | n/a | 22.6% | 32.4% |
Return vs Industry: Insufficient data to determine how SNZZ.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SNZZ.F performed against the US Market.
Price Volatility
| SNZZ.F volatility | |
|---|---|
| SNZZ.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNZZ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SNZZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 52 | Philip Siberg | www.senzime.com |
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd.
Senzime AB (publ) Fundamentals Summary
| SNZZ.F fundamental statistics | |
|---|---|
| Market cap | US$59.15m |
| Earnings (TTM) | -US$11.95m |
| Revenue (TTM) | US$5.03m |
11.8x
P/S Ratio-4.9x
P/E RatioIs SNZZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNZZ.F income statement (TTM) | |
|---|---|
| Revenue | SEK 55.29m |
| Cost of Revenue | SEK 36.90m |
| Gross Profit | SEK 18.40m |
| Other Expenses | SEK 149.86m |
| Earnings | -SEK 131.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 17, 2025
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 33.27% |
| Net Profit Margin | -237.75% |
| Debt/Equity Ratio | 0% |
How did SNZZ.F perform over the long term?
See historical performance and comparison